GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Short Percentage of Float

BeiGene (STU:49B) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of BeiGene's Short Percentage of Float

For the Biotechnology subindustry, BeiGene's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeiGene's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where BeiGene's Short Percentage of Float falls into.


;
;

BeiGene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (STU:49B) » Definitions » Short Percentage of Float
Comparable Companies
ALNY BNTX SMMT INSM BMRN RPRX MRNA INCY EXEL ASND VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB XKRX:068270 HKSE:02269 XKRX:196170 OCSE:GMAB
Traded in Other Exchanges
ONC:USA 06160:Hong Kong 688235:China B1ME34:Brazil
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Website
https://www.beigene.com
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines